-ciclib
A CDK inhibitor, blocking the cyclin-dependent kinases that move cells through division; palbociclib, ribociclib and abemaciclib treat breast cancer.
- Drugs ending in -ciclib: 35
- Approved somewhere: 4
- With a US drug page: 4
- Stem
- -ciclib
- Class
- Drugs that block cyclin-dependent kinases (CDKs)
Approved and clinical-stage drugs in ChEMBL whose names ending in -ciclib, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Abemaciclib | Approved | CDK4, CDK6 | Cyclin-dependent kinase 4 inhibitor |
| Palbociclib | Approved | CCND1, CDK6, CCND1, CDK4 | CDK6/cyclin D1 inhibitor |
| Ribociclib | Approved | CDK4, CDK6 | Cyclin-dependent kinase 4 inhibitor |
| Trilaciclib | Approved | CDK4, CDK6 | Cyclin-dependent kinase 4 inhibitor |
| Dalpiciclib | Phase 3 | — | — |
| Dinaciclib | Phase 3 | CDK1, CDK2, CDK5, CDK9 | Cyclin-dependent kinase 1 inhibitor |
| Lerociclib | Phase 3 | — | — |
| Asnuciclib | Phase 2 | — | — |
| Atirmociclib | Phase 2 | — | — |
| Crozbaciclib | Phase 2 | — | — |
| Culmerciclib | Phase 2 | — | — |
| Ebvaciclib | Phase 2 | — | — |
| Eciruciclib | Phase 2 | — | — |
| Fovinaciclib | Phase 2 | — | — |
| Inixaciclib | Phase 2 | — | — |
| Milciclib | Phase 2 | CDK1, CDK2, CDK4, NTRK1 | Cyclin-dependent kinase 1 inhibitor |
| Mocaciclib | Phase 2 | — | — |
| Narazaciclib | Phase 2 | — | — |
| Roniciclib | Phase 2 | Cyclin-dependent kinase | Cyclin-dependent kinase inhibitor |
| Seliciclib | Phase 2 | CDK2, CDK7, CDK9, CDK1 and 1 more | Cyclin-dependent kinase 2 inhibitor |
| Tacaciclib | Phase 2 | — | — |
| Tambiciclib | Phase 2 | — | — |
| Tibremciclib | Phase 2 | — | — |
| Ulecaciclib | Phase 2 | — | — |
| Zemirciclib | Phase 2 | — | — |
| Atuveciclib | Phase 1 | — | — |
| Avotaciclib | Phase 1 | — | — |
| Briciclib | Phase 1 | CCND1 | G1/S-specific cyclin D1 inhibitor |
| Certociclib | Phase 1 | — | — |
| Enitociclib | Phase 1 | — | — |
| Istisociclib | Phase 1 | — | — |
| Tegtociclib | Phase 1 | — | — |
| Voruciclib | Phase 1 | CDK4 | Cyclin-dependent kinase 4 inhibitor |
| Zotiraciclib | Phase 1 | CDK1, CDK2, CDK7, CDK9 and 2 more | Cyclin-dependent kinase 1 inhibitor |
| Riviciclib | — | CDK1, CDK4, CDK9 | Cyclin-dependent kinase 1 inhibitor |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO